CRISPR Therapeutics
Baarerstrasse 14, Zug, CH-6300, Switzerland
Overview
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 9
Sector focus
- Biopharma
- Biotechnology
- Genetics
- Medical
Investment portfolio
- Exsilio Therapeutics
Participated · Series A · Jun 2024
Exsilio Therapeutics develops genomic medicines designed to permanently insert therapeutic genes via RNA intermediate templates and deliver them in lipid nanoparticles. Its technology is based on naturally occurring genetic elements engineered through predictive in silico modeling and wet lab experimentation for precise insertion into safe-harbor sites of disease-relevant cells. The company aims to treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions, by encoding genes that integrate permanently rather than producing transient effects. Exsilio plans to use its platform to insert whole genes with a repeatable and titratable approach, potentially addressing patients irrespective of individual mutations. Led by CEO Tal Zaks, the company intends to advance lead candidates toward development and expand operations using the new financing. The article does not disclose revenue or user metrics.